Prion protein — mediator of toxicity in multiple proteinopathies (original) (raw)
- News & Views
- Published: 02 March 2020
NEURODEGENERATIVE DISEASE
Nature Reviews Neurology volume 16, pages 187–188 (2020)Cite this article
- 1337 Accesses
- 4 Citations
- 19 Altmetric
- Metrics details
Subjects
A new study shows that interactions of the cellular prion protein with amyloid-β, tau and α-synuclein oligomers are important in mediating the toxicity of these proteins in Alzheimer disease and Parkinson disease. The findings suggest a shared pathway that could be a therapeutic target common to multiple neurodegenerative diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model
- Grace M. Lloyd
- , Jess-Karan S. Dhillon
- … David R. Borchelt
Molecular Neurodegeneration Open Access 09 September 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
References
- Prusiner, S. B. A unifying role for prions in neurodegenerative diseases. Science 336, 1511–1513 (2012).
Article CAS Google Scholar - Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101–112 (2007).
Article CAS Google Scholar - Corbett, G. T. et al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 139, 503–526 (2019).
Article Google Scholar - Bessen, R. A. & Marsh, R. F. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68, 7859–7868 (1994).
Article CAS Google Scholar - Smith, L. M., Kostylev, M. A., Lee, S. & Strittmatter, S. M. Systematic and standardized comparison of reported amyloid-beta receptors for sufficiency, affinity, and Alzheimer’s disease relevance. J. Biol. Chem. 294, 6042–6053 (2019).
Article CAS Google Scholar - Guerrero-Ferreira, R. et al. Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. eLife 8, e48907 (2019).
Article Google Scholar - Zhang, W. et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. eLife 8, e43584 (2019).
Article Google Scholar - Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron 79, 887–902 (2013).
Article CAS Google Scholar - Friberg, K. N. et al. Intracerebral infusion of antisense oligonucleotides into prion-infected mice. Mol. Ther. Nucleic Acids 1, e9 (2012).
Article Google Scholar - Raymond, G. J. et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight 5, 131175 (2019).
Article Google Scholar
Acknowledgements
The authors thank Nick A. Paras for useful discussions.
Author information
Authors and Affiliations
- Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA
Jacob I. Ayers & Stanley B. Prusiner - Department of Neurology, University of California, San Francisco, CA, USA
Jacob I. Ayers & Stanley B. Prusiner - Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
Stanley B. Prusiner
Authors
- Jacob I. Ayers
You can also search for this author inPubMed Google Scholar - Stanley B. Prusiner
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toStanley B. Prusiner.
Ethics declarations
Competing interests
The Institute for Neurodegenerative Diseases has a research collaboration with Daiichi Sankyo (Tokyo, Japan). S.B.P. is a member of the Scientific Advisory Board of ViewPoint Therapeutics and a member of the Board of Directors of Trizell. J.I.A. declares no competing interests.
Rights and permissions
About this article
Cite this article
Ayers, J.I., Prusiner, S.B. Prion protein — mediator of toxicity in multiple proteinopathies.Nat Rev Neurol 16, 187–188 (2020). https://doi.org/10.1038/s41582-020-0332-8
- Published: 02 March 2020
- Issue Date: April 2020
- DOI: https://doi.org/10.1038/s41582-020-0332-8